Systemic polyarteritis nodosa in the young: A single-center experience over thirty-two years

Arthritis and Rheumatism

Volumn 65, Issue 9, 2013, Pages 2476-2485

  Eleftheriou, Despina ^a   Dillon, Michael J ^a   Tullus, Kjell ^a   Marks, Stephen D ^a   Pilkington, Clarissa A ^a   Roebuck, Derek J ^a   Klein, Nigel J ^a   Brogan, Paul A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPYRIDAMOLE; ETANERCEPT; HYDROXYCHLOROQUINE; ILOPROST; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADOLESCENT; ARTERIOGRAPHY; ARTICLE; CHILD; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYALGIA; NECROTIZING ARTERITIS; NEUROLOGIC DISEASE; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SKIN BIOPSY; SKIN DISEASE; SYMPTOM;

ADOLESCENT; ADRENAL CORTEX HORMONES; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; PLASMA EXCHANGE; POLYARTERITIS NODOSA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84883209347     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38024     Document Type: Article

References (35)

1. Kussmaul A, Maier R,. Ueber eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med 1866; 1: 484-518.
2. Dillon MJ, Eleftheriou D, Brogan PA,. Medium-size-vessel vasculitis. Pediatr Nephrol 2010; 25: 1641-52.
3. Watts RA, Scott DG,. Epidemiology of vasculitis. In:, Ball GV, Bridges SL, editors. Vasculitis. 2nd ed. Oxford: Oxford University Press; 2008. p. 7-21.
4. Ettlinger RE, Nelson AM, Burke EC, Lie JT,. Polyarteritis nodosa in childhood: a clinical pathologic study. Arthritis Rheum 1979; 22: 820-5.
5. Besbas N, Ozen S, Saatci U, Topalog-clu R, Tinaztepe K, Bakkaloglu A,. Renal involvement in polyarteritis nodosa: evaluation of 26 Turkish children. Pediatr Nephrol 2000; 14: 325-7.
6. Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr 2004; 145: 517-22.
7. Ozen S, Besbas N, Saatci U, Bakkaloglu A,. Diagnostic criteria for polyarteritis nodosa in childhood. J Pediatr 1992; 120: 206-9.
8. Brogan PA, Davies R, Gordon I, Dillon MJ,. Renal angiography in children with polyarteritis nodosa. Pediatr Nephrol 2002; 17: 277-83.
9. Dillon MJ,. Classification and pathogenesis of arteritis in children. Toxicol Pathol 1989; 17: 214-8.
10. Dillon MJ,. Vasculitic syndromes. In:, Woo P, White PH, Ansell BM, editors. Paediatric rheumatology update. Oxford: Oxford University Press; 1990. p. 227-42.
11. Dillon MJ,. Diagnosis and clinical management of childhood vasculitic disease. Vasc Med Rev 1993; 4: 133-43.
12. Kumar L, Thapa BR, Sarkar B, Walia BN,. Benign cutaneous polyarteritis nodosa in children below 10 years of age-a clinical experience. Ann Rheum Dis 1995; 54: 134-6.
13. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 2010; 69: 798-806.
14. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65: 936-41.
15. Dolezalova P, Price-Kuehne FE, Ozen S, Benseler SM, Cabral DA, Anton J, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 2012. E-pub ahead of print.
16. Rees L, Brogan PA, Bockenhauer D, Webb NJ, editors. Paediatric nephrology. 2nd ed. Oxford: Oxford University Press; 2012.
17. Collett D,. Modelling survival data in medical research. London: Chapman & Hall; 1994.
18. Brogan PA, Shah V, Dillon MJ,. Polyarteritis nodosa in childhood [abstract]. Cleve Clin J Med 2002; 69 (Suppl II): SII-179.
19. Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 2009; 48: 978-86.
20. Leavitt RY, Fauci AS,. Polyangiitis overlap syndrome: classification and prospective clinical experience. Am J Med 1986; 81: 79-85.
21. Miller DL,. Angiography in polyarteritis nodosa [letter]. AJR Am J Roentgenol 2000; 175: 1747-8.
22. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, et al, and the French Cooperative Study Group for Vasculitides. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol 1997; 36: 1290-7.
23. Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Genereau T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: a prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-45.
24. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-7.
25. Foster H, Brogan PA, editors. Paediatric rheumatology. Oxford: Oxford University Press; 2012.
26. Feng PH, George CR, Evans RA, Murkin GE, Spicer E, Thomas BS, et al. Cyclophosphamide and infertility. Lancet 1972; 1: 840.
27. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87: 524-30.
28. Arulkumaran N, Jawad S, Smith SW, Harper L, Brogan P, Pusey CD, et al. Long-term outcome of paediatric patients with ANCA vasculitis. Pediatr Rheumatol 2011; 9: 1-7.
29. Booth AD, Wallace S, McEniery CM, Brown J, Jayne DR, Wilkinson IB,. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004; 50: 581-8.
30. Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term followup. Ann Rheum Dis 2012; 71: 955-60.
31. Brogan PA, Malik M, Shah N, Kilday JP, Ramsay A, Shah V, et al. Systemic vasculitis: a cause of indeterminate intestinal inflammation. J Pediatr Gastroenterol Nutr 2006; 42: 405-15.
32. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 17-28.
33. Dillon MJ,. Diagnosis and management of vasculitides in childhood. Br J Rheumatol 1994; 33: 187-92.
34. Cheung YF, Brogan PA, Pilla CB, Dillon MJ, Redington AN,. Arterial distensibility in children and teenagers: normal evolution and the effect of childhood vasculitis. Arch Dis Child 2002; 87: 348-51.
35. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.